We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.91B
1-Year Est. Return 304.52%
This Fund
S&P 500
This Quarter Est. Return
+14.28%
1 Year Est. Return
+304.52%
3 Year Est. Return
+591.72%
5 Year Est. Return
+1,391.92%
10 Year Est. Return
+28,184.58%
AUM
$3.14B
AUM Growth
+$168M
Cap. Flow
-$21.7M
Cap. Flow %
-0.69%
Top 10 Hldgs %
62.21%
Holding
45
New
4
Increased
10
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$62M
2
NKTR icon
Nektar Therapeutics
NKTR
+$56.9M
3
IRON icon
Disc Medicine
IRON
+$43.2M
4
STRO icon
Sutro Biopharma
STRO
+$22.6M
5
AVR
Anteris Technologies
AVR
+$17.2M

Top Sells

Rank Stock Value
1
ABVX
Abivax
ABVX
+$68.5M
2
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$62.1M
3
RVMD icon
Revolution Medicines
RVMD
+$50.5M
4
RPTX
Repare Therapeutics
RPTX
+$26.9M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$15.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.92%
2 Miscellaneous 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYMR icon
1
Kymera Therapeutics
KYMR
$9.82B
$458M 14.6%
5,502,710
– –
MLTX icon
2
MoonLake Immunotherapeutics
MLTX
$1.28B
$298M 9.5%
16,001,284
-3,750,000
-19% -$62.1M
RVMD icon
3
Revolution Medicines
RVMD
$44.6B
$278M 8.85%
2,856,782
-500,000
-15% -$50.5M
NKTR icon
4
Nektar Therapeutics
NKTR
$2.48B
$184M 5.87%
2,559,595
+1,000,000
+64% +$56.9M
GPCR icon
5
Structure Therapeutics
GPCR
$3.38B
$167M 5.31%
3,459,358
-19,664
-0.6% -$1.35M
MIRM icon
6
Mirum Pharmaceuticals
MIRM
$5.94B
$146M 4.66%
1,584,727
+89,437
+6% +$8.41M
GHRS icon
7
GH Research
GHRS
$1.92B
$122M 3.87%
8,650,158
-177,554
-2% -$2.73M
PVLA
8
Palvella Therapeutics
PVLA
$2.16B
$120M 3.82%
960,989
+81,980
+9% +$8.55M
ZYME icon
9
Zymeworks
ZYME
$2.02B
$93.5M 2.98%
3,734,142
-204,499
-5% -$4.84M
XNCR icon
10
Xencor
XNCR
$1.94B
$86M 2.74%
7,133,720
– –
STOK icon
11
Stoke Therapeutics
STOK
$2.04B
$82.9M 2.64%
2,547,557
+281,883
+12% +$9.24M
CGEM icon
12
Cullinan Oncology
CGEM
$1.4B
$81.7M 2.6%
5,750,683
– –
IRON icon
13
Disc Medicine
IRON
$3.07B
$81.4M 2.59%
1,272,312
+622,312
+96% +$43.2M
XOMA
14
DELISTED
Xoma
XOMA
$81.3M 2.59%
2,590,303
– –
OLMA icon
15
Olema Pharmaceuticals
OLMA
$899M
$79M 2.52%
5,295,893
– –
TYRA icon
16
Tyra Biosciences
TYRA
$1.49B
$75.7M 2.41%
1,976,196
-151,469
-7% -$4.9M
GLUE icon
17
Monte Rosa Therapeutics
GLUE
$1.14B
$73.4M 2.34%
4,460,886
+625,000
+16% +$12M
ALKS icon
18
Alkermes
ALKS
$7.95B
$70.7M 2.25%
+2,000,000
New +$62M
KURA icon
19
Kura Oncology
KURA
$1.13B
$68.7M 2.19%
8,445,769
-171,393
-2% -$1.47M
ACIU icon
20
AC Immune
ACIU
$263M
$54.5M 1.74%
19,822,436
– –
CBIO
21
Crescent Biopharma
CBIO
$659M
$50.5M 1.61%
2,748,763
– –
ANNX icon
22
Annexon
ANNX
$942M
$48.2M 1.54%
8,698,173
-429,907
-5% -$2.42M
CMPX icon
23
Compass Therapeutics
CMPX
$432M
$41.1M 1.31%
7,764,842
– –
IMCR icon
24
Immunocore
IMCR
$1.89B
$39M 1.24%
1,294,463
-194,512
-13% -$6.29M
SEPN
25
Septerna Inc
SEPN
$1.82B
$32.5M 1.04%
1,353,249
-367,533
-21% -$9.66M
1
2

Similar funds

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
LNC
Lincoln National Corp Radnor, Pennsylvania $3.91B AUM 14.77% 1-Year Est. Return
GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
AC
Anther Capital Hong Kong $3.91B AUM
FFGIM
Founders Fund Growth II Management San Francisco, California $3.9B AUM
AIM
ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

BVF Inc's Q1 2026 Portfolio in Review

As of Q1 2026, BVF Inc held 45 positions worth $3.14B, up 5.7% from $2.97B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

BVF Inc's Q1 2026 filing shows 4 new, 10 increased, 11 reduced and 4 closed positions. Its largest new stake was Alkermes: 2,000,000 shares worth $70.7M. The largest sale was Abivax, an estimated $68.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

  • BVF Inc's largest Q1 2026 buy was Alkermes: 2,000,000 shares worth $70.7M.
  • BVF Inc added most to Nektar Therapeutics in Q1 2026, an estimated $56.9M increase.
  • BVF Inc's biggest Q1 2026 reduction was MoonLake Immunotherapeutics, cutting an estimated $62.1M.
  • BVF Inc fully exited Abivax in Q1 2026, selling an estimated $68.5M.
  • BVF Inc's ten largest holdings make up 62% of its $3.14B portfolio in Q1 2026.
  • BVF Inc opened 4 new positions and closed 4 in Q1 2026.
  • BVF Inc's portfolio value rose 5.7% quarter-over-quarter to $3.14B.

Based on BVF Inc's 13F filing for Q1 2026, filed 15 May 2026.